Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | LATS1 | O95835 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1632262 | 0.77 | MLYCD (0.33) | MLYCD | |
| SCHEMBL1630787 | 0.76 | DGAT1 (0.35) | MLYCDDGAT1 | |
| SCHEMBL1630712 | 0.72 | DGAT1 (0.32) | DGAT1 | |
| SCHEMBL1632253 | 0.70 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL27797021 | 0.68 | NAALAD2 (0.35) | MLYCDALDH1A1 | |
| SCHEMBL1630836 | 0.68 | MMP8 (0.36) | — | |
| SCHEMBL10005804 | 0.67 | DGAT1 (0.34) | ALDH1A1DGAT1 | |
| SCHEMBL19169471 | 0.65 | DGAT1 (0.39) | ALDH1A1DGAT1 | |
| SCHEMBL27818651 | 0.64 | MLYCD (0.33) | MLYCD | |
| SCHEMBL14533429 | 0.64 | DGAT1 (0.35) | ALDH1A1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932240-B2 | Phosphadiazine HCV polymerase inhibitors IV | IDENIX PHARMACEUTICALS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932240-B2 | Phosphadiazine HCV polymerase inhibitors IV | IDENIX PHARMACEUTICALS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-20090081158-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20090081158-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090081158-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV | POLI, ITPA, POLR2H | MLYCD 1712/4885ALDH1A1 1722/4885DGAT1 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.